Recombinant Vaccines Market to Reach USD 25.32 Billion by 2027; Technological Advancement in Proteomics and Genetics to Stimulate Growth

The global recombinant vaccines market size is expected to reach USD 25.32 billion by 2027. The implementation of vaccination programs and government policies to eliminate the burden of deadliest viruses will have an excellent effect on the global market, states Fortune Business Insights, in a report, titled “Recombinant Vaccines Market Size, Share & COVID-19 Impact Analysis, By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus (HPV), Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2020-2027.” The market size stood at USD 10.82 billion in 2019 and is expected to exhibit of 11.3% between 2020 and 2027.

Collaboration of Sanofi and BARDA for COVID-19 Vaccine to Amplify Market Sales

Sanofi Pasteur, a French multinational pharmaceutical company headquartered in Paris, France announced that has been working on the SARS vaccine, which can help in the development of the COVID-19 vaccine. Sanofi has partnered with Biomedical Advanced Research and Development Authority (BARDA), thus extending its long-term contract with BARDA. Sanofi declared that it would be using a recombinant DNA platform to develop the coronavirus vaccine candidate. As recombinant technology generates accurate genetic match to proteins found on the surface of the virus, thus, it is considered a trail-blazing technology against the virus. Moreover, the DNA sequence combined with the DNA of the baculovirus expression platform will help in the development of recombinant influenza products. The method will also result in the production of large quantities of the coronavirus antigen. The long-term agreement between BARDA and Sanofi will positively provide solutions to combat deadly health threats. The ongoing exploration of vaccines and innovative technologies by the company will contribute to the pandemic crisis, which, in turn, will offer impetus to the market.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/recombinant-vaccines-market-101935

Innovations in Recombinant DNA to Improve Market Potential 

The growing technological advancements in recombinant DNA technology, genetics, and proteomics will create lucrative business opportunities for the market. The growing knowledge about the advantages of recombinant vaccine production will impel pharma companies to develop recombinant vaccines for a variety of infectious diseases such as COVID-19 and Hepatitis B and others. The robust government support and funding for research will consequently facilitate the healthy growth of the market in the foreseeable future. The ongoing clinical trials for effective vaccines will spur a lucrative business opening for the industry in the foreseeable future.

Strong Distribution Network of Leading Players to Consolidate Position

The leading players such as GlaxoSmithKline plc and Merck Co are focused on strengthening its portfolio and distribution network to reinforce its position in the market. The robust portfolio of GSK includes recombinant vaccines for human papillomavirus, hepatitis B, rotavirus, and others. The company’s herpes zoster is one of its top-selling vaccines. The companies are also fixed on launching novel vaccines especially in the time of pandemics.  The increasing competition among pharma companies for Covid-19 vaccines will further improve market possibilities. Also, the product pipeline and trails will have a tremendous impact on the market.

The Report Lists the Main Companies in the Recombinant Vaccines Market:

• GlaxoSmithKline plc. (U.K, Europe)


• Merck & Co., Inc (New Jersey, U.S)


• Dynavax Technologies (California, U.S)


• Pfizer Inc (New York, U.S)


• Sanofi S.A (France, Europe)


• Serum Institute of India Pvt. Ltd (India, Asia Pacific)


• Novartis AG (Switzerland, Europe)


• Other Prominent Players

Further Report Findings:

• Regional Analysis: Europe is expected to witness a rapid growth rate during the forecast period. The growth in the region is attributed to the rising incidence of diseases. The adoption of immunization policies in European countries such as the UK, France, and Germany will aid the healthy growth of the market. The vast government support will enable speedy expansion of the market in the forthcoming years.


• Leading Segment: Subunit vaccines are expected to account for the largest share in the global market due to its effectiveness against diseases such as HPV, hepatitis B, and others. Moreover, the heavy investment for the development of subunit vaccines will promote the segment, which, in turn, will boost the market.

The Market is Segmented into: